# Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Source: https://nuclide.cc/trials/nct06754085/  
Nuclide record `nct06754085` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Florastamin[18F] Injection in prostate cancer, run by HTA Co., Ltd., completed in June 2026 with no results posted yet.

## Summary

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06754085 by HTA Co., Ltd., with 131 participants enrolled (actual), started 2024-12-19 and completed on 2026-06-11 (primary completion and study completion both actual, per ClinicalTrials.gov, last updated 2026-09-25). Interventions recorded: Florastamin[18F] Injection.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06754085
- Phase: 3
- Setting: A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
- Sponsor: HTA Co., Ltd.
- Enrolled: 131

## Sources

- ClinicalTrials.gov NCT06754085: https://clinicaltrials.gov/study/NCT06754085

## Connected records

- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [PET (positron emission tomography)](https://nuclide.cc/technologies/pet/), [PET/CT](https://nuclide.cc/technologies/pet-ct/)
- drugs: [Florastamin F-18](https://nuclide.cc/drugs/florastamin-f18/)

---
JSON: https://nuclide.cc/api/v1/entities/nct06754085.json